Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Travera Inc
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
City of Hope Medical Center
Kaiser Permanente
Washington University School of Medicine
City of Hope Medical Center
University of Nebraska
Eli Lilly and Company
Var2 Pharmaceuticals
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Sensei Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Tempus AI
Esperas Pharma Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Immunophotonics, Inc.
Taproot Health
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
pharmaand GmbH
Kineta Inc.
Aesculap AG
Case Comprehensive Cancer Center
University Medicine Greifswald
Genzada Pharmaceuticals USA, Inc.
Roswell Park Cancer Institute
MacroGenics
SpeciCare
Stanford University
Swiss Cancer Institute
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MedInnovation GmbH
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences